Command Palette

Search for a command to run...

Preprint WatchModerateJuly 11th, 2026

Argininosuccinate Synthase 1 links hepatic urea cycle to whole body lipid metabolism

Kim, L. C.; Lesner, N. P.; Cai, X.; Han, X.; Jung, J. W.; Xu, J. P.; Coffey, N. J.; Zheng, D.; Brown, M. L.; Mesaros, C.; Arany, Z.; Simon, M. C.

Loss of the urea cycle enzyme ASS1 links hepatic nitrogen handling to whole-body lipid metabolism and contributes to liver disease and hepatocellular carcinoma progression.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

The indexed ASS1 failure is pegargiminase (ADI-PEG 20), an arginine-depleting agent that exploits ASS1 loss in tumors and did not improve outcomes in the Phase 3 leiomyosarcoma study documented in pegargiminase-ass1-leiomyosarcoma-argsarc-phase3-efficacy-failure. This preprint reports that ASS1 links the hepatic urea cycle to whole-body lipid metabolism, which extends ASS1 biology beyond arginine synthesis into systemic nitrogen and lipid handling. It studies liver metabolism and hepatocellular carcinoma rather than leiomyosarcoma, so it neither replicates nor overturns the arginine-auxotrophy rationale directly. The relevant point is that systemic arginine deprivation targets a node with broad metabolic roles, consistent with the difficulty of turning ASS1 dependence into a durable single-agent effect.

Abstract excerpt

The hepatic urea cycle is consistently suppressed in liver disease and hepatocellular carcinoma (HCC), but whether loss of individual enzymes contributes to disease initiation and progression remains unknown. Using mice with hepatocyte-specific deletion of argininosuccinate synthase 1 (ASS1), the urea cycle enzyme that condenses citrulline and aspartate into argininosuccinate, we investigated the role of ASS1 in diet and carcinogen-induced liver disease progression. We found that complete loss of hepatic Ass1 is lethal, but high fat diet extends lifespan. Unexpectedly, animals with approximately 85% loss of hepatic Ass1 are completed protected from diet-induced obesity, liver steatosis, fibrosis, and HCC. We determined that hepatic Ass1 loss activates fatty acid oxidation in peripheral oxidative tissues leading to increased energy expenditure and protection from disease phenotypes. Moreover, targeting Ass1 after obesity onset promotes weight loss and reverses liver steatosis. These findings implicate hepatic ASS1 as a novel regulator of whole-body lipid metabolism that can be targeted to prevent obesity, liver disease, and HCC.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.